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Finding powerful predictors in guiding prostate cancer
treatment strategy and modalities is an important goal
of urologists. These markers may also serve as new 
targets for prostate cancer therapy.
Deregulation of apoptosis is involved in prostate can-
cer development and progression. p21(WAF1/CIP1)
and p27(kip1) proteins are key cell cycle regulators
and parts of cyclin-dependent kinase (Cdks), which are
important factors involved in the regulation of cellu-
lar proliferation and programmed death (apoptosis).
p27(kip1) protein binds to cyclin-E-Cdk2 and coun-
teracts cell mitosis, and is frequently mutated in various
human cancers.1 p21(WAF1/CIP1) and p27(kip1)
proteins are closely related to p53molecules with onco-
genic properties. The commonly mutated p53 oncogene
is related to carcinogenesis and disease progression of
cancers, including bladder and prostate cancers.
In human prostate cancer, the frequent down-
regulation of p27(kip1) protein expression is correlated
with poor clinical outcomes.2 It possesses dosage-
sensitive positive as well as negative modulatory roles
in prostate cancer progression. Drug and gene target
therapy trials targeting p27(kip1) have been conducted
in animals.3,4 The preliminary results are promising.
In this issue, Wu et al conclude that p21(WAF1/
CIP1) and p27(kip1) protein expression have no role
in predicting biochemical relapse for stage pT2 prostate
cancers based on study results from limited cases.5
The methodologies used in performing immunohis-
tochemistry and cutoff point selection in reading will
usually influence the outcomes. Nevertheless, the use
of both p21 and p27 proteins in correlation with
Gleason score, tumor grade,6 and serum prostate spe-
cific antigen level,7 and in predicting the likelihood 
of therapeutic response and survival in patients with
prostate cancer8 remain controversial. Further large-
scale evaluation of both apoptosis-related markers in
prostate cancer is needed before we can consolidate
these conclusions.
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